EP4320147A4 - MULTIFUNCTIONAL TCR-BINDING MOLECULES AND THEIR USES - Google Patents

MULTIFUNCTIONAL TCR-BINDING MOLECULES AND THEIR USES

Info

Publication number
EP4320147A4
EP4320147A4 EP22785489.0A EP22785489A EP4320147A4 EP 4320147 A4 EP4320147 A4 EP 4320147A4 EP 22785489 A EP22785489 A EP 22785489A EP 4320147 A4 EP4320147 A4 EP 4320147A4
Authority
EP
European Patent Office
Prior art keywords
tcr
multifunctional
binding molecules
molecules
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22785489.0A
Other languages
German (de)
French (fr)
Other versions
EP4320147A2 (en
Inventor
Andreas Loew
Jonathan Hsu
Madan Katragadda
Gurkan Guntas
Sangeetha Palakurthi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marengo Therapeutics Inc
Original Assignee
Marengo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marengo Therapeutics Inc filed Critical Marengo Therapeutics Inc
Publication of EP4320147A2 publication Critical patent/EP4320147A2/en
Publication of EP4320147A4 publication Critical patent/EP4320147A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP22785489.0A 2021-04-08 2022-04-07 MULTIFUNCTIONAL TCR-BINDING MOLECULES AND THEIR USES Pending EP4320147A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163172468P 2021-04-08 2021-04-08
PCT/US2022/023922 WO2022216993A2 (en) 2021-04-08 2022-04-07 Multifuntional molecules binding to tcr and uses thereof

Publications (2)

Publication Number Publication Date
EP4320147A2 EP4320147A2 (en) 2024-02-14
EP4320147A4 true EP4320147A4 (en) 2025-06-18

Family

ID=83546591

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22785489.0A Pending EP4320147A4 (en) 2021-04-08 2022-04-07 MULTIFUNCTIONAL TCR-BINDING MOLECULES AND THEIR USES

Country Status (10)

Country Link
US (1) US20250099579A1 (en)
EP (1) EP4320147A4 (en)
JP (1) JP2024515591A (en)
KR (1) KR20240004462A (en)
CN (1) CN117597359A (en)
AU (1) AU2022255506A1 (en)
BR (1) BR112023020832A2 (en)
CA (1) CA3214757A1 (en)
GB (2) GB2643481A (en)
WO (1) WO2022216993A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (en) 2019-02-21 2024-11-29 马伦戈治疗公司 Antibody molecules that bind to NKP30 and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
KR20250143365A (en) * 2022-10-12 2025-10-01 마렝고 테라퓨틱스, 인크. Multifunctional molecules binding to TCR and uses thereof
WO2024226532A2 (en) * 2023-04-24 2024-10-31 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
CN116554356B (en) * 2023-05-16 2024-01-23 武汉大学 Fusion protein of hyper IL-15, sCD4 and Fc and application thereof
WO2025217371A2 (en) * 2024-04-12 2025-10-16 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2025222066A1 (en) * 2024-04-17 2025-10-23 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020172596A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof

Family Cites Families (230)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US861745A (en) 1906-11-21 1907-07-30 Jefferson D Maxwell Hydraulic dredging apparatus.
EP0000151B1 (en) 1977-06-28 1981-05-20 Sandoz Ag 1-substituted aminoindolines, process for their production and pharmaceutical compositions containing them
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
US5731116A (en) 1989-05-17 1998-03-24 Dai Nippon Printing Co., Ltd. Electrostatic information recording medium and electrostatic information recording and reproducing method
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (en) 1990-07-10 2000-04-17 Cambridge Antibody Tech Process for producing specific binding pair elements
DE69133557D1 (en) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv HOMOLOGOUS RECOMBINATION IN MAMMALIAN CELLS
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (en) 1991-04-10 2008-12-15 Scripps Research Inst LIBRARIES OF HETERODIMER RECEPTORS USING PHAGEMIDS
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
DE69233408T2 (en) 1991-12-02 2005-09-22 Cambridge Antibody Technology Ltd., Melbourn Production of Antibodies on Phage Surfaces Starting from Antibody Segment Libraries.
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JP3980657B2 (en) 1992-06-26 2007-09-26 生化学工業株式会社 Chondroitinase ABC, process for producing the same and pharmaceutical composition
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DK1621554T4 (en) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobulins devoid of light chains
ATE404683T1 (en) 1992-09-25 2008-08-15 Aventis Pharma Sa ADENOVIRUS VECTORS FOR TRANSFER OF FOREIGN GENES INTO CELLS OF THE CENTRAL NERVOUS SYSTEM, ESPECIALLY IN THE BRAIN
ES2162863T3 (en) 1993-04-29 2002-01-16 Unilever Nv PRODUCTION OF ANTIBODIES OR FRAGMENTS (FUNCTIONALIZED) OF THE SAME DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF CAMELIDAE.
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
GB9325182D0 (en) 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
SE9400088D0 (en) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
FR2727867B1 (en) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa GENE TRANSFER IN MEDULLAR MOTONURONES USING ADENOVIRAL VECTORS
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DK1137941T4 (en) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein scaffolds for antibody mimetics and other binding proteins
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
WO2000060070A1 (en) 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
DE19932688B4 (en) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design of beta-sheet proteins of gamma-II-crystalline antibody-like
CN100447244C (en) 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 BAFF receptor (BCMA), an immunomodulator
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
US7105149B1 (en) 1999-11-29 2006-09-12 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/myeloma
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
JP2003531588A (en) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド Multivalent antibodies and their uses
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
DK1399484T3 (en) 2001-06-28 2010-11-08 Domantis Ltd Double-specific ligand and its use
US20040009530A1 (en) 2002-01-16 2004-01-15 Wilson David S. Engineered binding proteins
US20080267965A1 (en) 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
DK2314629T4 (en) 2002-07-18 2023-02-06 Merus Nv RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES
CN101899114A (en) 2002-12-23 2010-12-01 惠氏公司 Anti-PD-1 antibody and uses thereof
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
US20090005257A1 (en) 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
DE10324447A1 (en) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generation of artificial binding proteins based on ubiquitin
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
DE602004017726D1 (en) 2003-06-30 2008-12-24 Domantis Ltd Pegylated single-domain antibodies (dAb)
JP2007509064A (en) 2003-10-20 2007-04-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment regimen for BAFF antagonists
KR20060132006A (en) 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. Receptor Coupling Agents and Their Therapeutic Uses
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
CA2575402A1 (en) 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
WO2006039238A2 (en) 2004-09-30 2006-04-13 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Irta2 antibodies and methods of use
KR20070115881A (en) 2005-01-12 2007-12-06 메다렉스, 인코포레이티드 AIArtie-2 antibody and uses thereof
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7431380B1 (en) 2005-02-24 2008-10-07 Theodore Allen Buresh Louver kit
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DK2439273T3 (en) 2005-05-09 2019-06-03 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH-1 (PD-1) AND PROCEDURES FOR TREATMENT OF CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNTER APPLICATIONS
PT1907424E (en) 2005-07-01 2015-10-09 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
PT1999154E (en) 2006-03-24 2013-01-24 Merck Patent Gmbh Engineered heterodimeric protein domains
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
BR122017025062B8 (en) 2007-06-18 2021-07-27 Merck Sharp & Dohme monoclonal antibody or antibody fragment to human programmed death receptor pd-1, polynucleotide and composition comprising said antibody or fragment
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP6157046B2 (en) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド Method for generating antibody Fc heterodimer molecules using electrostatic steering effect
CN101970499B (en) 2008-02-11 2014-12-31 治疗科技公司 Monoclonal Antibodies for Cancer Therapy
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme BINDING PROTEINS WITH PD-1
KR102057826B1 (en) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
JP2012500855A (en) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド PD-1 antagonists and methods for treating infectious diseases
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (en) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ PD-1 antibody and PD-L1 antibody and use thereof
MX341884B (en) 2009-03-10 2016-09-07 Biogen Ma Inc Anti-bcma antibodies.
RU2583270C2 (en) 2009-04-01 2016-05-10 Дженентек, Инк. ANTIBODIES TO FcRH5, THEIR IMMUNOCONJUGATES AND METHODS OF THEIR USE
RU2587621C2 (en) 2009-04-01 2016-06-20 Дженентек, Инк. ANTI-FcRH5 ANTIBODIES, IMMUNOCONJUGATES THEREOF AND METHODS FOR USE THEREOF
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
IT1395574B1 (en) 2009-09-14 2012-10-16 Guala Dispensing Spa DISTRIBUTION DEVICE
MX340971B (en) 2009-11-23 2016-08-02 Amgen Inc * Monomeric antibody fc.
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
CN102770456B (en) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 Multispecific antibodies, antibody analogs, compositions and methods
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
CN103261220B (en) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 For generating the method for polyspecific and multivalent antibody
CN103068846B9 (en) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 Bispecific antibodies comprising disulfide-stabilized Fv fragments
CN103068847B (en) 2010-08-24 2019-05-07 罗切格利卡特公司 Activatable Bispecific Antibodies
ES2758994T3 (en) 2010-11-05 2020-05-07 Zymeworks Inc Stable heterodimeric antibody design with mutations in the Fc domain
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
US20120213768A1 (en) 2011-02-19 2012-08-23 Baylor Research Institute Diagnostic and Therapeutic Uses for B Cell Maturation Antigen
BR112013023918A2 (en) 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa hetero-dimeric immunoglobulin or hetero-dimeric fragment thereof, method for producing a hetero-dimeric immunoglobulin or hetero-dimeric fragment thereof, method for constructing a protein-protein interface of a domain of a multi-domain protein and use of a domain donor of a first and second member of a naturally occurring immunoglobulin superfamily
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
TWI687439B (en) 2011-06-30 2020-03-11 中外製藥股份有限公司 Heterodimerized polypeptide
UA117901C2 (en) 2011-07-06 2018-10-25 Ґенмаб Б.В. METHOD FOR STRENGTHENING THE EFFECTORAL FUNCTION OF THE ORIGINAL POLYEPEPTIDE, ITS OPTIONS AND THEIR APPLICATIONS
NO2748201T3 (en) 2011-08-23 2018-05-12
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
PT2768857T (en) 2011-10-19 2020-01-27 Novimmune Sa Methods of purifying antibodies
BR112014010580B1 (en) 2011-11-04 2021-01-12 Zymeworks, Inc. isolated heteromultimeric fc construct, composition, use of an isolated heteromultimeric fc construct, nucleic acid composition and method for expressing the isolated heteromultimeric fc construct
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
KR101764096B1 (en) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 Anti-pd-l1 antibodies and uses thereof
RS60499B1 (en) 2011-12-20 2020-08-31 Medimmune Llc Modified polypeptides for bispecific antibody scaffolds
CN104185642A (en) 2011-12-27 2014-12-03 财团法人生物技术开发中心 Light chain-bridged bispecific antibodies
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
EP3517548A1 (en) 2012-03-13 2019-07-31 NovImmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
EP2825553B1 (en) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
AU2013259276B2 (en) 2012-05-10 2018-03-22 Bioatla Llc Multi-specific monoclonal antibodies
MX2014014162A (en) 2012-05-24 2015-02-04 Hoffmann La Roche Multispecific antibodies.
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
WO2014001326A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
UY34887A (en) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
CN104736174B (en) 2012-07-06 2019-06-14 根马布私人有限公司 Dimeric protein with triple mutation
IN2015DN01299A (en) 2012-07-23 2015-07-03 Zymeworks Inc
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JP2015524821A (en) 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー Antibody or fusion protein multimerized via cysteine mutation and μ tail
EP2904093B1 (en) 2012-10-03 2019-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
RU2015117393A (en) 2012-10-08 2016-12-10 Роше Гликарт Аг Deprived fc antibodies containing two Fab fragments, and methods for their use
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
EP2934577A1 (en) 2012-12-19 2015-10-28 Adimab, LLC Multivalent antibody analogs, and methods of their preparation and use
ES2876009T3 (en) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Heterodimerized polypeptide
KR20200024345A (en) 2013-01-10 2020-03-06 젠맵 비. 브이 Human igg1 fc region variants and uses thereof
WO2014116846A2 (en) 2013-01-23 2014-07-31 Abbvie, Inc. Methods and compositions for modulating an immune response
TWI635098B (en) 2013-02-01 2018-09-11 再生元醫藥公司 Antibody containing chimeric constant region
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
US10047163B2 (en) 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
WO2014138306A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Engager cells for immunotherapy
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
AR095374A1 (en) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh UNION MOLECULES FOR BCMA AND CD3
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
ES2821753T3 (en) 2013-03-15 2021-04-27 Lilly Co Eli Fab and bispecific antibody production procedures
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2014177459A2 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
CA2913363A1 (en) 2013-05-24 2014-11-27 Zymeworks Inc. Modular protein drug conjugate therapeutic
KR102332303B1 (en) 2013-05-31 2021-11-26 자임워크스 인코포레이티드 Heteromultimers with reduced or silenced effector function
TWI725931B (en) 2013-06-24 2021-05-01 美商建南德克公司 Anti-fcrh5 antibodies
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES2881306T3 (en) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Method for the production of heteromultimers of polypeptides
GB201317928D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Molecule
BR112016006929A2 (en) 2013-10-11 2017-09-19 Hoffmann La Roche ANTIBODY, NUCLEIC ACID, EXPRESSION VECTOR, HOST CELL, METHODS OF PREPARING ANTIBODY, TREATMENT OF PATIENTS AND GENERATION OF AN ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE OF THE ANTIBODY
IL263466B2 (en) 2013-12-17 2023-10-01 Genentech Inc Anti-cd3 antibodies and methods of use
CN113248613B (en) 2014-01-15 2024-08-23 豪夫迈·罗氏有限公司 Fc region variants with modified FCRN binding properties
MX380658B (en) 2014-01-15 2025-03-11 Hoffmann La Roche REGION FC VARIANTS WITH ENHANCED PROTEIN A BINDING.
RU2727639C2 (en) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Variants of fc-region with modified ability to bind to fcrn and with preserved ability to bind with protein a
EP3107565A4 (en) 2014-02-21 2017-08-23 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
UA117289C2 (en) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг MULTISPECIFIC ANTIBODY
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
KR102526945B1 (en) 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Humanized antibodies against cd269(bcma)
CA3244731A1 (en) 2014-05-28 2025-11-29 Zymeworks Bc Inc. Modified antigen binding polypeptide constructs and uses thereof
WO2015197598A2 (en) 2014-06-27 2015-12-30 Innate Pharma Multispecific antigen binding proteins
WO2015197582A1 (en) 2014-06-27 2015-12-30 Innate Pharma Monomeric multispecific antigen binding proteins
EP3174897B1 (en) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3177643B1 (en) 2014-08-04 2019-05-08 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
CA2960569A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-Laroche Ag Fc-region variants with modified fcrn- and protein a-binding properties
DK3215528T3 (en) 2014-11-06 2019-10-07 Hoffmann La Roche Fc region variants with modified FcRn binding and methods of use
DK3221357T3 (en) 2014-11-20 2020-08-10 Hoffmann La Roche Common light chains and methods of use
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
WO2016087650A1 (en) 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody
SI3226897T1 (en) 2014-12-05 2021-08-31 Memorial Sloan Kettering Cancer Center Antibodies targeting B-cell maturation antigen and methods of administration
SI3242890T1 (en) 2015-01-08 2020-01-31 BioNTech SE Agonistic tnf receptor binding agents
CA2973720A1 (en) 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
IL308212A (en) 2015-01-20 2024-01-01 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
ES3006358T3 (en) 2015-03-13 2025-03-18 Novimmune Sa Methods of purifying bispecific antibodies
AU2016249981B2 (en) 2015-04-13 2022-02-17 Five Prime Therapeutics, Inc. Combination therapy for cancer
TWI703159B (en) 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma-specific therapeutic antibodies and their uses
DK3310814T5 (en) 2015-06-16 2024-10-07 Hoffmann La Roche Humanized and affinity matured antibodies against FcRH5 and methods of use
US9914777B2 (en) 2015-07-10 2018-03-13 Merus N.V. Human CD3 binding antibody
MX2018000948A (en) 2015-07-23 2018-09-27 Inhibrx Inc Multivalent and multispecific gitr-binding fusion proteins.
SI3331910T1 (en) 2015-08-03 2020-07-31 Engmab Sarl Monoclonal antibodies against human b cell maturation antigen (bcma)
MX2018002043A (en) 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTI-BCMA ANTIBODIES, BSPECIFIC ANTIGEN-BINDING MOLLICULES THAT BIND BCMA AND CD3, AND USES THEREOF.
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
JP7274413B2 (en) 2016-09-23 2023-05-16 マレンゴ・セラピューティクス，インコーポレーテッド Multispecific antibody molecules containing lambda and kappa light chains
CN110437339B (en) * 2018-05-04 2021-08-13 免疫靶向有限公司 Fusion protein type prodrug with interleukin 15 as active component
CA3105448A1 (en) * 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7737306B2 (en) * 2019-02-21 2025-09-10 マレンゴ・セラピューティクス，インコーポレーテッド Multifunctional molecules that bind to T cells and their use for treating autoimmune disorders
EP3927746A1 (en) * 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2020416273A1 (en) * 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
US12445327B2 (en) * 2020-02-24 2025-10-14 Lg Electronics Inc. Method and apparatus for transceiving and receiving wireless signal in wireless communication system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020172596A1 (en) * 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HSU JONATHAN ET AL: "A T cell receptor [beta] chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity", SCIENCE TRANSLATIONAL MEDICINE(SUPPLEMENTARY MATERIALS), vol. 15, no. 724, 1 November 2023 (2023-11-01), pages eadi0258 - eadi0258, XP093274356, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.adi0258 *
MURER PATRIZIA ET AL: "Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation", NEW BIOTECHNOLOGY, vol. 52, 1 September 2019 (2019-09-01), NL, pages 42 - 53, XP093007294, ISSN: 1871-6784, DOI: 10.1016/j.nbt.2019.04.002 *
See also references of WO2022216993A2 *
VANTOUROUR P ET AL.: "Innate TCR[beta]-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentials", 8 December 2023 (2023-12-08), XP093274402, Retrieved from the Internet <URL:https://www.science.org/doi/full/10.1126/sciadv.adj6174?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org> *

Also Published As

Publication number Publication date
GB2643481A (en) 2026-02-18
WO2022216993A2 (en) 2022-10-13
JP2024515591A (en) 2024-04-10
CA3214757A1 (en) 2022-10-13
EP4320147A2 (en) 2024-02-14
BR112023020832A2 (en) 2023-12-19
CN117597359A (en) 2024-02-23
WO2022216993A3 (en) 2022-11-17
KR20240004462A (en) 2024-01-11
GB202315700D0 (en) 2023-11-29
GB2623199A (en) 2024-04-10
US20250099579A1 (en) 2025-03-27
AU2022255506A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
EP4320147A4 (en) MULTIFUNCTIONAL TCR-BINDING MOLECULES AND THEIR USES
EP4453039A4 (en) MULTIFUNCTIONAL MOLECULES THAT BIND TO TCR AND THEIR USES
EP4085076A4 (en) ANTIBODIES BINDING TO BCMA AND THEIR USES
EP4240773A4 (en) NANOBODIES BINDING TO TROP2 AND THEIR USES
EP4117682A4 (en) MODIFIED NUCLEOTIDES AND THEIR USES
MA43186A (en) ANTIBODIES SPECIFICALLY BINDING TO PD-1 AND THEIR USES
EP3958910A4 (en) ANTI-CD45-DRUG ANTIBODY CONJUGATES AND THEIR USES
EP3849608A4 (en) NEW ANTI-LILRB4 ANTIBODIES AND THEIR USES
EP3765524A4 (en) ANTIBODIES THAT BIND TO CD39 AND THEIR USES
MA49457A (en) CD73 BINDING ANTIBODY MOLECULES AND THEIR USES
MA52785A (en) BINDING MOLECULES DIRECTED AGAINST BCMA AND THEIR USES
EP4100439A4 (en) NEW ANTI-LILRB2 ANTIBODIES AND THEIR USES
MA53750A (en) ANTI-BCMA ANTIBODIES, B-SPECIFIC ANTIGEN BINDING MOLECULES WHICH BIND TO BCMA AND CD3 AND THEIR USES
EP4204450A4 (en) MULTIFUNCTIONAL MOLECULES BINDING TO CALRETICULIN AND USES THEREOF
EP3481430A4 (en) NUCLEIC ACID CONJUGATES AND USES THEREOF
EP4196153A4 (en) RAS NEOANTIGENS AND THEIR USES
EP4388009A4 (en) ANTI-CCR8 ANTIBODIES AND THEIR USES
EP3487533A4 (en) MULTIMERIC MOLECULES ATTACHING OX40 AND USES THEREOF
EP4093768A4 (en) CAL-T CONSTRUCTIONS AND THEIR USES
EP3781202A4 (en) PD-1 BINDING ANTIBODIES AND THEIR USES
EP3515948A4 (en) COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF
MA41480A (en) ANTIBODIES BOUND TO CCR6 AND THEIR USES
EP4126229A4 (en) MTORC1 MODULATORS AND THEIR USES
EP3962954A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES
EP4126018A4 (en) ANTIBODIES BINDING TO CD40 AND THEIR USES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231013

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40107768

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20250519

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20250513BHEP

Ipc: C07K 16/28 20060101ALI20250513BHEP

Ipc: C07K 14/725 20060101AFI20250513BHEP